After three years of work the Food and Drug Administration (FDA) released its final Risk Evaluation and Mitigation Strategies (REMS) for extend-release (ER) and long-acting (LA) opioid medications. This is the first time that the FDA has mandated a class wide REMS and much of what is recommended will be looked at closely for future […]
Tag Archives: Continuing education
CME, FDA, REMS
FDA REMS: Blue Print for Prescriber Continuing Education Program for Extended Release-Long Acting Opioids
08
Nov
Nov
The Food and Drug Administration (FDA) released a “Blueprint for Prescriber Continuing Education Program” regarding the use of opioids. The draft Blueprint contains core messages intended for use by continuing education (CE) providers to develop educational materials to train prescribers of long-acting and extended release opioids under the required risk evaluation and mitigation strategy (REMS) for these […]
In 2007, the Josiah Macy Foundation (JMF) sponsored a conference, which identified the need for improving continuing education (CE) in the health professions. A report was then created incorporating the conferences findings, and covered issues such as: – Decreasing the focus on the didactic lecture as the primary format for CE; – Increasing […]